Analyst Price Targets — CERT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 6:08 pm | Michael Cherny | Leerink Partners | $10.00 | $6.61 | StreetInsider | Certara Inc. (CERT) PT Lowered to $10 at Leerink Partners |
| January 6, 2026 12:33 pm | Certara to Outperform | Leerink Partners | $13.00 | $9.04 | TheFly | Certara upgraded to Outperform from Market Perform at Leerink |
| November 21, 2025 9:45 am | — | Redburn Partners | $10.00 | $8.03 | TheFly | Certara initiated with a Buy at Rothschild & Co Redburn |
| September 29, 2025 11:13 am | — | Craig-Hallum | $16.00 | $11.80 | TheFly | Certara initiated with a Buy at Craig-Hallum |
| November 5, 2024 11:50 am | Joe Vruwink | Robert W. Baird | $13.00 | $10.31 | StreetInsider | Certara Inc. (CERT) PT Lowered to $13 at Baird |
| September 27, 2024 5:22 am | Dan Leonard | UBS | $16.00 | $10.70 | TheFly | Certara upgraded to Buy from Neutral at UBS |
| June 28, 2024 5:28 am | Luke Sergott | Barclays | $16.00 | $13.65 | TheFly | Certara price target lowered to $16 from $18 at Barclays |
| April 10, 2024 1:31 am | Scott Schoenhaus | KeyBanc | $23.00 | $18.51 | StreetInsider | KeyBanc Upgrades Certara Inc. (CERT) to Overweight |
| November 14, 2022 7:29 am | — | Credit Suisse | $20.00 | $14.65 | Benzinga | Credit Suisse Maintains Outperform on Certara, Lowers Price Target to $20 |
| July 1, 2022 4:42 am | Jeff Garro | Piper Sandler | $28.00 | $21.46 | TheFly | Certara initiated with an Overweight at Piper Sandler |
Latest News for CERT
Certara, Inc. (CERT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix®).
The Touchstone Small Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell 2000® Index, for the quarter ended December 31, 2025. The best performing stocks based on relative performance vs. the benchmark during the quarter included White Mountains Insurance Group, Revolve Group Inc. and Haemonetics Corp. The more challenged positions based on relative performance during the quarter included…
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CERT.
U.S. House Trading
No House trades found for CERT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.